Viralytics Ltd (ASX:VLA) has reported positive results from a Phase 1b clinical trial of late-stage melanoma cancer patients in multiple U.S. sites evaluating the safety and anti-cancer activity endpoints of CAVATAK coupled with a cancer drug YERVOY.
There were 11 advanced melanoma patients enrolled to date.
The preliminary finding from the investigator is that out of five patients not previously treated with YERVOY, four had clinically meaningful tumor regressions in sites injected with CAVATAK in patients with advanced melanoma.
The initial findings confirm that systemic immunity against melanoma can be achieved with this combination. The study is ongoing with updates in coming months.
There were no dose limiting toxicities, and no CAVATAK-related grade 3 or higher adverse events.
The results add to the clinical and preclinical evidence pointing to CAVATAK’s potential to enhance the activity of checkpoint inhibitors across a range of cancer indications.
CAVATAK and YERVOY are a new class of cancer treatments known as immunotherapies, designed to enhance the body’s own defences in fighting cancer.
CAVATAK is currently being studied in Phase 1 and 2 clinical trials for the treatment of melanoma, as well as prostate, bladder and lung cancers.
In December 2015, Viralytics completed a share placement that raised $28.4 million at $0.615 per share.
Additionally, Viralytics raised $4 million via a share purchase plan to retail investors in January 2016, following applications well in excess of $10 million.
Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.